Investigational Drug Information for TD-1473
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the drug development status for TD-1473?
TD-1473 is an investigational drug.
There have been 10 clinical trials for TD-1473. The most recent clinical trial was a Phase 1 trial, which was initiated on July 23rd 2020.
The most common disease conditions in clinical trials are Inflammatory Bowel Diseases, Ulcer, and Colitis, Ulcerative. The leading clinical trial sponsors are Theravance Biopharma, Theravance Biopharma R & D, Inc., and Mayo Clinic.
There is one US patent protecting this investigational drug and forty-eight international patents.
Summary for TD-1473
|US Patent Applications||12|
|WIPO Patent Applications||3|
|Japanese Patent Applications||0|
|Clinical Trial Progress||Phase 1 (2020-07-23)|
Recent Clinical Trials for TD-1473
|Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects||Theravance Biopharma||Phase 1|
|TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study||Theravance Biopharma||Phase 2/Phase 3|
|Rifaximin in Patients With Diabetic Gastroparesis||Mayo Clinic||Phase 2|
Clinical Trial Summary for TD-1473
Top disease conditions for TD-1473
Top clinical trial sponsors for TD-1473
US Patents for TD-1473
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|TD-1473||⤷ Try a Trial||Substituted naphthyridines as JAK kinase inhibitors||Theravance Biopharma R&D IP, LLC (South San Francisco, CA)||⤷ Try a Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for TD-1473
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|TD-1473||Australia||AU2016267141||2035-05-28||⤷ Try a Trial|
|TD-1473||Australia||AU2020202181||2035-05-28||⤷ Try a Trial|
|TD-1473||Brazil||BR112017025542||2035-05-28||⤷ Try a Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|